8 studies found for:    Open Studies | "Splenomegaly"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Splenomegaly"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Not yet recruiting Prednisone Plus Chloroquine for the Treatment of Hyper-reactive Malarial Splenomegaly
Conditions: Hyper-reactive Malarial Splenomegaly;   Malaria;   Anaemia
Interventions: Drug: prednisone induction - chloroquine;   Drug: Chloroquine
2 Not yet recruiting The Use of Point-of-Care Ultrasound in the Diagnosis of Acute Infectious Mononucleosis in the Emergency Department
Conditions: Infectious Mononucleosis;   Splenomegaly
Intervention: Device: Point-of-care ultrasound
3 Recruiting CINC424A2X01B Rollover Protocol
Condition: Splenomegaly
Intervention: Drug: Ruxolitinib
4 Unknown  Study of the Impact of Hypersplenism and Splenectomy on Hepatocarcinogenesis in Patients With Posthepatitic Cirrhosis
Conditions: Liver Cirrhosis;   Carcinoma, Hepatocellular;   Splenomegaly;   Laparotomy
5 Recruiting Natural History of Noncirrhotic Portal Hypertension
Conditions: Cystic Fibrosis;   Immunologic Deficiency Syndrome;   Turner Syndrome;   Congenital Hepatic Fibrosis;   Idiopathic Non-Cirrhotic Portal Hypertension
6 Recruiting Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
Conditions: Primary Myelofibrosis;   Post-polycythemia Vera Myelofibrosis;   Post-essential Thrombocythemia Myelofibrosis
Interventions: Drug: Pacritinib;   Drug: Best Available Therapy
7 Unknown  Hemolysis in Patients With Hereditary Spherocytosis (HS)
Conditions: Hereditary;   Hemolysis
Intervention: Other: fermented papaya preparation (FPP)
8 Recruiting Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.
Condition: Thalassemia Major
Intervention: Drug: INC424 (ruxolitinib)

Indicates status has not been verified in more than two years